S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
Log in

NYSE:PKI - PerkinElmer Stock Price, Forecast & News

$101.32
+0.10 (+0.10 %)
(As of 01/21/2020 04:00 PM ET)
Today's Range
$101.15
Now: $101.32
$101.82
50-Day Range
$91.49
MA: $97.04
$101.73
52-Week Range
$78.35
Now: $101.32
$103.00
Volume853,800 shs
Average Volume577,179 shs
Market Capitalization$11.26 billion
P/E Ratio48.25
Dividend Yield0.28%
Beta1.3
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
CUSIP71404610
Phone781-663-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.78 billion
Cash Flow$5.44 per share
Book Value$23.24 per share

Profitability

Net Income$237.93 million

Miscellaneous

Employees12,500
Market Cap$11.26 billion
Next Earnings Date1/27/2020 (Confirmed)
OptionableOptionable

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Simple Options Trading for Beginners retails on Amazon for $19.95 and has 4 out of 5 stars. It was written by a stock market trading veteran with over 44 years of experience. Because of a special promotion, this book is 100% FREE for you today.

PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer announced a quarterly dividend on Thursday, October 24th. Shareholders of record on Friday, January 17th will be given a dividend of $0.07 per share on Friday, February 7th. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date is Thursday, January 16th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) posted its quarterly earnings results on Wednesday, October, 30th. The medical research company reported $1.06 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.01 by $0.05. The medical research company had revenue of $706.92 million for the quarter, compared to analyst estimates of $722.69 million. PerkinElmer had a return on equity of 16.45% and a net margin of 8.27%. The business's quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.90 earnings per share. View PerkinElmer's Earnings History.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Monday, January 27th 2020. View Earnings Estimates for PerkinElmer.

How can I listen to PerkinElmer's earnings call?

PerkinElmer will be holding an earnings conference call on Monday, January 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share guidance of $4.07 for the period, compared to the Thomson Reuters consensus estimate of $4.03.

What price target have analysts set for PKI?

13 brokerages have issued twelve-month target prices for PerkinElmer's shares. Their forecasts range from $41.00 to $115.00. On average, they anticipate PerkinElmer's stock price to reach $84.46 in the next year. This suggests that the stock has a possible downside of 16.6%. View Analyst Price Targets for PerkinElmer.

What is the consensus analysts' recommendation for PerkinElmer?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

News coverage about PKI stock has trended positive on Tuesday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PerkinElmer earned a coverage optimism score of 2.2 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for PerkinElmer.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include NVIDIA (NVDA), AbbVie (ABBV), IBM (IBM), Visa (V), Alibaba Group (BABA), salesforce.com (CRM), Thermo Fisher Scientific (TMO), Adobe (ADBE), Cisco Systems (CSCO) and Home Depot (HD).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:
  • Mr. Robert F. Friel, Chairman & CEO (Age 63)
  • Dr. Prahlad R. Singh, Pres & COO (Age 54)
  • Mr. James M. Mock, Sr. VP & CFO (Age 42)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)
  • Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56)

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Artemis Investment Management LLP (0.19%), Boston Trust Walden Corp (0.14%), First National Bank of Omaha (0.08%), Nisa Investment Advisors LLC (0.07%), Commerzbank Aktiengesellschaft FI (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.02%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

Which major investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Nisa Investment Advisors LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, State of Alaska Department of Revenue, Tributary Capital Management LLC and Wealthfront Advisers LLC. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Peter Barrett and Prahlad R Singh. View Insider Buying and Selling for PerkinElmer.

Which major investors are buying PerkinElmer stock?

PKI stock was acquired by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., First Hawaiian Bank, Boston Trust Walden Corp, Zurcher Kantonalbank Zurich Cantonalbank , AE Wealth Management LLC, Rockland Trust Co., Prentiss Smith & Co. Inc. and Commerzbank Aktiengesellschaft FI. View Insider Buying and Selling for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $101.32.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $11.26 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.93 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.View Additional Information About PerkinElmer.

What is PerkinElmer's official website?

The official website for PerkinElmer is http://www.perkinelmer.com/.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  457 (Vote Outperform)
Underperform Votes:  469 (Vote Underperform)
Total Votes:  926
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel